SynthesisMedical science monitor : international medical journal of experimental and clinical research2019
Association of RAGE rs1800625 Polymorphism and Cancer Risk: A Meta-Analysis of 18 Case-Control Studies.
Synthesis in Medical science monitor : international medical journal of experimental and clinical research, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The impact of advanced glycation end products and their receptors on the development and prognosis of colorectal cancer.BMC cancer · 2026Pooled it
- Article
- Contributions of the receptor for advanced glycation end products axis activation in gastric cancer.World journal of gastroenterology · 2023Review
- The impact of receptor of advanced glycation end-products polymorphisms on prostate cancer progression and clinicopathological characteristics.Journal of cellular and molecular medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Accumulating evidence suggests that the rs1800625 polymorphism in RAGE promoter region might be associated with cancer risk; however, data from different studies show conflicting results. Here, a meta-analysis was conducted to evaluate the associations between RAGE rs1800625 polymorphism and cancer risk. MATERIAL AND METHODS We searched Embase (Excerpt Medica Database), PubMed, and CNKI (Chinese National Knowledge Infrastructure) databases until March 15, 2019 to identify potential studies for the meta-analysis. RESULTS Eighteen eligible studies were included in the current meta-analysis, representing 6246 cases and 6819 controls. Pooled analysis showed positive correlation between the RAGE rs1800625 polymorphism and susceptibility of cancer in recessive genetic model [CC versus TC+TT: odds ratio (OR)=1.397, 95% confidence interval (CI): 1.031-1.894, P=0.031]. Subgroup analysis revealed this association in the Asian, but not Caucasian population, and this correlation was not detected in either breast or lung cancer. Sensitivity analysis indicated unstable results, which should be interpreted with caution. No publication bias was observed. CONCLUSIONS In conclusion, the RAGE rs1800625 polymorphism was associated with increased overall cancer risk in Asians in recessive genetic model. However, large-scale and well-designed studies in different populations and diverse cancer types are needed for a precise conclusion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.